贝达药业：公司与康万达共同开发的抗体-溶瘤病毒组合疗法（V113+BK-001）正在按计划推进中

Core Viewpoint - The collaboration between the company and Kangwanda on the VM-001 project is progressing as planned, with updates to be disclosed at significant milestones [1] Group 1 - The company is jointly developing an antibody-oncolytic virus combination therapy (V113+BK-001) with Kangwanda [1] - The company will provide timely announcements regarding any major developments in the project [1]